MarketMoodz
Cardinal Health mixed results spotlight margin pressure; plan for CAH stock
Cardinal Health reported quarterly revenue of $60.94 billion and adjusted EPS of $3.17, beating the earnings print but lagging the topline consensus. Tariffs weighed on Global Medical Products & Distribution even as GLP-1 demand boosted Pharmaceutical & Specialty Solutions, prompting a raised full-year guidance and a more nuanced investor outlook.
Key Takeaways
- Revenue for the quarter was $60.94 billion, up 11% year over year, vs consensus of $61.7 billion.
- Adjusted EPS was $3.17, above consensus of $2.79; full-year 2026 adjusted EPS guidance raised to $10.70-$10.80.
- Pharmaceutical & Specialty Solutions revenue rose to $56.2 billion, up 11% YoY, with GLP-1 growth contributing about 6 percentage points.
- Global Medical Products & Distribution revenue was $3.25 billion, flat YoY, with segment profit down 35% due to tariffs.
- Other segment revenue rose 31% to $1.7 billion; free cash flow beat Street consensus by roughly 3x.
People Involved
- Aaron AltCardinal Health CFO
Entities Involved
- Cardinal Health, Inc.Global healthcare services and products company
MarketMoodz Analysis
For investors, the quarter underscores earnings quality amid margin pressures from tariffs and a shifting demand mix for GLP-1 medications. The EPS beat supports a more constructive near-term view, but much of the 2026 guidance uplift comes from non-operational factors such as taxes, buybacks and interest costs, suggesting limited operating leverage to offset ongoing tariff headwinds.
Historically, distributors in healthcare face volatility from policy shifts and tariff regimes. Cardinal Health’s mix—strong cash flow from non-operational drivers, resilient NPHS/At-Home segments, and a clearer path to margin improvement if tariff pressure eases—creates potential for multiple re-rating if core profitability improves. Key near-term catalysts include a steadier tariff environment, a healthier product mix, and stronger free cash flow delivery; risks include ongoing tariff exposure, slower distribution volumes, and IRA-related policy changes.
Source: Original Article